The tumor stroma, consisting of non-malignant cells and the extracellular matrix, undergoes significant quantitative and qualitative changes throughout malignant transformation and tumor progression. With increasing recognition of the role of the tumor microenvironment in disease progression, stromal components of the tumor have become attractive targets for therapeutic intervention. Stromal accumulation of the glycosaminoglycan hyaluronan occurs in many tumor types and is frequently associated with a negative disease prognosis. Hyaluronan interacts with other extracellular molecules as well as cellular receptors to form a complex interaction network influencing physicochemical properties, signal transduction, and biological behavior of cancer cells. In preclinical animal models, enzymatic removal of hyaluronan is associated with remodeling of the tumor stroma, reduction of tumor interstitial fluid pressure, expansion of tumor blood vessels and facilitated delivery of chemotherapy. This leads to inhibition of tumor growth and increased survival. Current evidence shows that abnormal accumulation of hyaluronan may be an important stromal target for cancer therapy. In this review we highlight the role of hyaluronan and hyaluronan-mediated interactions in cancer, and discuss historical and recent data on hyaluronidase-based therapies and the effect of hyaluronan removal on tumor growth.
References
[1]
Sund, M.; Kalluri, R. Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev. 2009, 28, 177–183, doi:10.1007/s10555-008-9175-2.
[2]
Weinberg, R.A. Coevolution in the tumor microenvironment. Nat. Genet. 2008, 40, 494–495, doi:10.1038/ng0508-494.
[3]
Shimoda, M.; Mellody, K.T.; Orimo, A. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin. Cell Dev. Biol. 2010, 21, 19–25.
[4]
Johansson, A.; Ganss, R. Remodeling of tumor stroma and response to therapy. Cancers 2012, 4, 340–353, doi:10.3390/cancers4020340.
[5]
Bissell, M.J.; Hines, W.C. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 2011, 17, 320–329, doi:10.1038/nm.2328.
[6]
Shepard, H.M.; Brdlik, C.M.; Schreiber, H. Signal integration: A framework for understanding the efficacy of therapeutics targeting the human EGFR family. J. Clin. Invest. 2008, 118, 3574–3581, doi:10.1172/JCI36049.
[7]
Ferrara, N. VEGF as a therapeutic target in cancer. Oncology 2005, 69, 11–16, doi:10.1159/000088479.
[8]
Kelleher, F.C. Hedgehog signaling and therapeutics in pancreatic cancer. Carcinogenesis 2011, 32, 445–451, doi:10.1093/carcin/bgq280.
[9]
Liu, Q.; Sun, J.D.; Wang, J.; Ahluwalia, D.; Baker, A.F.; Cranmer, L.D.; Ferraro, D.; Wang, Y.; Duan, J.X.; Ammons, W.S.; et al. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: Optimization of dosing regimens and schedules. Cancer Chemother. Pharmacol. 2012, 69, 1487–1498.
[10]
Weiss, G.J.; Infante, J.R.; Chiorean, E.G.; Borad, M.J.; Bendell, J.C.; Molina, J.R.; Tibes, R.; Ramanathan, R.K.; Lewandowski, K.; Jones, S.F.; et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin. Cancer Res. 2011, 17, 2997–3004, doi:10.1158/1078-0432.CCR-10-3425.
[11]
Jacobetz, M.A.; Chan, D.S.; Neesse, A.; Bapiro, T.E.; Cook, N.; Frese, K.K.; Feig, C.; Nakagawa, T.; Caldwell, M.E.; Zecchini, H.I.; et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2012, doi:10.1136/gutjnl-2012-302529.
[12]
Provenzano, P.P.; Cuevas, C.; Chang, A.E.; Goel, V.K.; von Hoff, D.D.; Hingorani, S.R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21, 418–429, doi:10.1016/j.ccr.2012.01.007.
[13]
Jiang, P.; Li, X.; Thompson, C.B.; Huang, Z.; Araiza, F.; Osgood, R.; Wei, G.; Feldmann, M.; Frost, G.I.; Shepard, H.M. Effective targeting of the tumor microenvironment for cancer therapy. Anticancer Res. 2012, 32, 1203–1212.
Phase 1 Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors (Sponsor: Halozyme Therapeutics). Available online: http://clinicaltrials.gov/ct2/show/NCT01170897?term=NCT01170897&rank=1/ (accessed on 7 August 2012).
[16]
Phase 1B/2 Study of Gemcitabine + PEGPH20 versus Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer (Sponsor: Halozyme Therapeutics). Available online: http://clinicaltrials.gov/ct2/show/NCT01453153?term=NCT01453153&rank=1/ (accessed on 7 August 2012).
[17]
Weigel, P.H.; DeAngelis, P.L. Hyaluronan synthases: A decade-plus of novel glycosyltransferases. J. Biol. Chem. 2007, 282, 36777–36781.
[18]
Jokela, T.A.; Makkonen, K.M.; Oikari, S.; K？rn？, R.; Koli, E.; Hart, G.W.; Tammi, R.H.; Carlberg, C.; Tammi, M.I. Cellular content of UDP-N-acetylhexosamines controls hyaluronan synthase 2 expression and correlates with O-linked N-acetylglucosamine modification of transcription factors YY1 and SP1. J. Biol. Chem. 2011, 286, 33632–33640.
[19]
Itano, N.; Sawai, T.; Yoshida, M.; Lenas, P.; Yamada, Y.; Imagawa, M.; Shinomura, T.; Hamaguchi, M.; Yoshida, Y.; Ohnuki, Y.; et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J. Biol. Chem. 1999, 274, 25085–25092.
[20]
Viola, M.; Vigetti, D.; Genasetti, A.; Rizzi, M.; Karousou, E.; Moretto, P.; Clerici, M.; Bartolini, B.; Pallotti, F.; de Luca, G.; et al. Molecular control of the hyaluronan biosynthesis. Connect. Tissue Res. 2008, 49, 111–114, doi:10.1080/03008200802148405.
[21]
Li, L.; Asteriou, T.; Bernert, B.; Heldin, C.H.; Heldin, P. Growth factor regulation of hyaluronan synthesis and degradation in human dermal fibroblasts: Importance of hyaluronan for the mitogenic response of PDGF-BB. Biochem. J. 2007, 404, 327–336.
Camenisch, T.D.; Spicer, A.P.; Brehm-Gibson, T.; Biesterfeldt, J.; Augustine, M.L.; Calabro, A., Jr.; Kubalak, S.; Klewer, S.E.; McDonald, J.A. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J. Clin. Invest. 2000, 106, 349–360.
[24]
Tien, J.Y.; Spicer, A.P. Three vertebrate hyaluronan synthases are expressed during mouse development in distinct spatial and temporal patterns. Dev. Dyn. 2005, 233, 130–141, doi:10.1002/dvdy.20328.
[25]
Jokela, T. Regulation of hyaluronan synthesis by UDP-sugars. Ph.D. Thesis, University of Eastern Finland, Kuopio, Finland, 2011.
[26]
Toole, B.P. Hyaluronan: From extracellular glue to pericellular cue. Nat. Rev. Cancer 2004, 4, 528–539, doi:10.1038/nrc1391.
[27]
Spicer, A.P.; Tien, J.Y. Hyaluronan and morphogenesis. Birth Defects Res. C Embryo Today 2004, 72, 89–108, doi:10.1002/bdrc.20006.
[28]
Spicer, A.P.; Tien, J.L.; Joo, A.; Bowling, R.A., Jr. Investigation of hyaluronan function in the mouse through targeted mutagenesis. Glycoconj. J. 2002, 19, 341–345, doi:10.1023/A:1025321105691.
[29]
Koyama, H.; Hibi, T.; Isogai, Z.; Yoneda, M.; Fujimori, M.; Amano, J.; Kawakubo, M.; Kannagi, R.; Kimata, K.; Taniguchi, S.; et al. Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: Possible involvement of versican/PG-M. Am. J. Pathol. 2007, 170, 1086–1099.
[30]
Csoka, A.B.; Frost, G.I.; Stern, R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol. 2001, 20, 499–508, doi:10.1016/S0945-053X(01)00172-X.
[31]
Jadin, L.; Wu, X.; Ding, H.; Frost, G.I.; Onclinx, C.; Triggs-Raine, B.; Flamion, B. Skeletal and hematological anomalies in HYAL2-deficient mice: A second type of mucopolysaccharidosis IX? FASEB J. 2008, 22, 4316–4326, doi:10.1096/fj.08-111997.
[32]
Atmuri, V.; Martin, D.C.; Hemming, R.; Gutsol, A.; Byers, S.; Sahebjam, S.; Thliveris, J.A.; Mort, J.S.; Carmona, E.; Anderson, J.E.; et al. Hyaluronidase 3 (HYAL3) knockout mice do not display evidence of hyaluronan accumulation. Matrix Biol. 2008, 27, 653–660.
[33]
Martin, D.C.; Atmuri, V.; Hemming, R.J.; Farley, J.; Mort, J.S.; Byers, S.; Hombach-Klonisch, S.; Csoka, A.B.; Stern, R.; Triggs-Raine, B.L. A mouse model of human mucopolysaccharidosis IX exhibits osteoarthritis. Hum. Mol. Genet. 2008, 17, 1904–1915, doi:10.1093/hmg/ddn088.
[34]
Kimura, M.; Kim, E.; Kang, W.; Yamashita, M.; Saigo, M.; Yamazaki, T.; Nakanishi, T.; Kashiwabara, S.; Baba, T. Functional roles of mouse sperm hyaluronidases, HYAL5 and SPAM1, in fertilization. Biol. Reprod. 2009, 81, 939–947.
[35]
Triggs-Raine, B.; Salo, T.J.; Zhang, H.; Wicklow, B.A.; Natowicz, M.R. Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX. Proc. Natl. Acad. Sci. USA 1999, 96, 6296–6300.
[36]
Baba, D.; Kashiwabara, S.; Honda, A.; Yamagata, K.; Wu, Q.; Ikawa, M.; Okabe, M.; Baba, T. Mouse sperm lacking cell surface hyaluronidase PH-20 can pass through the layer of cumulus cells and fertilize the egg. J. Biol. Chem. 2002, 277, 30310–30314.
[37]
Wynne, C.; Harvey, V.; Schwabe, C.; Waaka, D.; McIntyre, C.; Bittner, B. Comparison of subcutaneous and intravenous administration of trastuzumab: A phase I/Ib trial in healthy male volunteers and patients With HER2-positive breast cancer. J. Clin. Pharmacol. 2012, doi:10.1177/0091270012436560.
[38]
Frost, G.I. Recombinant human hyaluronidase (rHuPH20): An enabling platform for subcutaneous drug and fluid administration. Expert Opin. Drug Deliv. 2007, 4, 427–440, doi:10.1517/17425247.4.4.427.
[39]
Bookbinder, L.H.; Hofer, A.; Haller, M.F.; Zepeda, M.L.; Keller, G.A.; Lim, J.E.; Edgington, T.S.; Shepard, H.M.; Patton, J.S.; Frost, G.I. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J. Control. Release 2006, 114, 230–241, doi:10.1016/j.jconrel.2006.05.027.
Tammi, R.H.; Kultti, A.; Kosma, V.M.; Pirinen, R.; Auvinen, P.; Tammi, M.I. Hyaluronan in human tumors: Pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin. Cancer Biol. 2008, 18, 288–295, doi:10.1016/j.semcancer.2008.03.005.
[42]
Simpson, M.A.; Lokeshwar, V.B. Hyaluronan and hyaluronidase in genitourinary tumors. Front. Biosci. 2008, 13, 5664–5680.
[43]
Itano, N.; Kimata, K. Altered hyaluronan biosynthesis in cancer progression. Semin. Cancer Biol. 2008, 18, 268–274, doi:10.1016/j.semcancer.2008.03.006.
[44]
Erickson, M.; Stern, R. Chain gangs: New aspects of hyaluronan metabolism. Biochem. Res. Int. 2012, 2012, 893947:1–893947:9.
[45]
Meyer, F.A. Macromolecular basis of globular protein exclusion and of swelling pressure in loose connective tissue (umbilical cord). Biochim. Biophys. Acta 1983, 755, 388–399, doi:10.1016/0304-4165(83)90242-8.
[46]
Jain, R.K. Delivery of molecular medicine to solid tumors: Lessons from in vivo imaging of gene expression and function. J. Control. Release 2001, 74, 7–25, doi:10.1016/S0168-3659(01)00306-6.
[47]
Jacobson, A.; Salnikov, A.; Lammerts, E.; Roswall, P.; Sundberg, C.; Heldin, P.; Rubin, K.; Heldin, N.E. Hyaluronan content in experimental carcinoma is not correlated to interstitial fluid pressure. Biochem. Biophys. Res. Commun. 2003, 305, 1017–1023.
[48]
Tse, J.M.; Cheng, G.; Tyrrell, J.A.; Wilcox-Adelman, S.A.; Boucher, Y.; Jain, R.K.; Munn, L.L. Mechanical compression drives cancer cells toward invasive phenotype. Proc. Natl. Acad. Sci. USA 2012, 109, 911–916.
[49]
Wang, S.; Basson, M.D. Akt directly regulates focal adhesion kinase through association and serine phosphorylation: Implication for pressure-induced colon cancer metastasis. Am. J. Physiol. Cell Physiol. 2011, 300, C657–C670, doi:10.1152/ajpcell.00377.2010.
[50]
Toole, B.P. Hyaluronan and its binding proteins, the hyaladherins. Curr. Opin. Cell Biol. 1990, 2, 839–844, doi:10.1016/0955-0674(90)90081-O.
[51]
Day, A.J. The structure and regulation of hyaluronan-binding proteins. Biochem. Soc. Trans. 1999, 27, 115–121.
[52]
Toole, B.P. Hyaluronan is not just a goo! J. Clin. Invest. 2000, 106, 335–336, doi:10.1172/JCI10706.
[53]
Varga, I.; Hutóczki, G.; Szemcsák, C.D.; Zahuczky, G.; Tóth, J.; Adamecz, Z.; Kenyeres, A.; Bognár, L.; Hanzély, Z.; Klekner, A. Brevican, neurocan, tenascin-C and versican are mainly responsible for the invasiveness of low-grade astrocytoma. Pathol. Oncol. Res. 2012, 18, 413–420, doi:10.1007/s12253-011-9461-0.
[54]
Kodama, J.; Hasengaowa; Kusumoto, T.; Seki, N.; Matsuo, T.; Nakamura, K.; Hongo, A.; Hiramatsu, Y. Versican expression in human cervical cancer. Eur. J. Cancer 2007, 43, 1460–1466.
[55]
Pukkila, M.; Kosunen, A.; Ropponen, K.; Virtaniemi, J.; Kellokoski, J.; Kumpulainen, E.; Pirinen, R.; Nuutinen, J.; Johansson, R.; Kosma, V.M. High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinoma. J. Clin. Pathol. 2007, 60, 267–272.
[56]
Said, N.; Sanchez-Carbayo, M.; Smith, S.C.; Theodorescu, D. RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J. Clin. Invest. 2012, 122, 1503–1518, doi:10.1172/JCI61392.
[57]
Wu, Y.J.; La Pierre, D.P.; Wu, J.; Yee, A.J.; Yang, B.B. The interaction of versican with its binding partners. Cell Res. 2005, 15, 483–494, doi:10.1038/sj.cr.7290318.
[58]
Aspberg, A.; Miura, R.; Bourdoulous, S.; Shimonaka, M.; Heinegard, D.; Schachner, M.; Ruoslahti, E.; Yamaguchi, Y. The C-type lectin domains of lecticans, a family of aggregating chondroitin sulfate proteoglycans, bind tenascin-R by protein-protein interactions independent of carbohydrate moiety. Proc. Natl. Acad. Sci. USA 1997, 94, 10116–10121.
[59]
Aspberg, A.; Adam, S.; Kostka, G.; Timpl, R.; Heineg？rd, D. Fibulin-1 is a ligand for the C-type lectin domains of aggrecan and versican. J. Biol. Chem. 1999, 274, 20444–20449.
[60]
Olin, A.I.; M？rgelin, M.; Sasaki, T.; Timpl, R.; Heineg？rd, D.; Aspberg, A. The proteoglycans aggrecan and Versican form networks with fibulin-2 through their lectin domain binding. J. Biol. Chem. 2001, 276, 1253–1261.
[61]
Yamagata, M.; Yamada, K.M.; Yoneda, M.; Suzuki, S.; Kimata, K. Chondroitin sulfate proteoglycan (PG-M-like proteoglycan) is involved in the binding of hyaluronic acid to cellular fibronectin. J. Biol. Chem. 1986, 261, 13526–13535.
[62]
Isogai, Z.; Aspberg, A.; Keene, D.R.; Ono, R.N.; Reinhardt, D.P.; Sakai, L.Y. Versican interacts with fibrillin-1 and links extracellular microfibrils to other connective tissue networks. J. Biol. Chem. 2002, 277, 4565–4572.
[63]
Mjaatvedt, C.H.; Yamamura, H.; Capehart, A.A.; Turner, D.; Markwald, R.R. The Cspg2 gene, disrupted in the hdf mutant, is required for right cardiac chamber and endocardial cushion formation. Dev. Biol. 1998, 202, 56–66, doi:10.1006/dbio.1998.9001.
[64]
Huang, L.; Yoneda, M.; Kimata, K. A serum-derived hyaluronan-associated protein (SHAP) is the heavy chain of the inter alpha-trypsin inhibitor. J. Biol. Chem. 1993, 268, 26725–26730.
[65]
Milner, C.M.; Tongsoongnoen, W.; Rugg, M.S.; Day, A.J. The molecular basis of inter-alpha-inhibitor heavy chain transfer on to hyaluronan. Biochem. Soc. Trans. 2007, 35, 672–676.
[66]
Yabushita, H.; Iwasaki, K.; Kanyama, K.; Obayashi, Y.; Zhuo, L.; Itano, N.; Kimata, K.; Wakatsuki, A. Clinicopathological role of serum-derived hyaluronan-associated protein (SHAP)-hyaluronan complex in endometrial cancer. Obstet. Gynecol. Int. 2011, 2011, 739150:1–739150:10.
[67]
Salustri, A.; Garlanda, C.; Hirsch, E.; de Acetis, M.; Maccagno, A.; Bottazzi, B.; Doni, A.; Bastone, A.; Mantovani, G.; Beck Peccoz, P.; et al. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development 2004, 131, 1577–1586.
[68]
Kuznetsova, S.A.; Day, A.J.; Mahoney, D.J.; Rugg, M.S.; Mosher, D.F.; Roberts, D.D. The N-terminal module of thrombospondin-1 interacts with the link domain of TSG-6 and enhances its covalent association with the heavy chains of inter-alpha-trypsin inhibitor. J. Biol. Chem. 2005, 280, 30899–30908.
Rilla, K.; Tiihonen, R.; Kultti, A.; Tammi, M.; Tammi, R. Pericellular hyaluronan coat visualized in live cells with a fluorescent probe is scaffolded by plasma membrane protrusions. J. Histochem. Cytochem. 2008, 56, 901–910, doi:10.1369/jhc.2008.951665.
[71]
Misra, S.; Toole, B.P.; Ghatak, S. Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J. Biol. Chem. 2006, 281, 34936–34941.
[72]
Toole, B.P. Hyaluronan-CD44 interactions in cancer: Paradoxes and possibilities. Clin. Cancer Res. 2009, 15, 7462–7468, doi:10.1158/1078-0432.CCR-09-0479.
[73]
Bennett, K.L.; Modrell, B.; Greenfield, B.; Bartolazzi, A.; Stamenkovic, I.; Peach, R.; Jackson, D.G.; Spring, F.; Aruffo, A. Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J. Cell Biol. 1995, 131, 1623–1633, doi:10.1083/jcb.131.6.1623.
[74]
Thankamony, S.P.; Knudson, W. Acylation of CD44 and its association with lipid rafts are required for receptor and hyaluronan endocytosis. J. Biol. Chem. 2006, 281, 34601–34609, doi:10.1074/jbc.M601530200.
[75]
Bourguignon, L.Y. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin. Cancer Biol. 2008, 18, 251–259, doi:10.1016/j.semcancer.2008.03.007.
[76]
Bourguignon, L.Y. Hyaluronan-Mediated CD44 Interaction with Receptor and Non-Receptor Kinases Promotes Oncogenic Signaling, Cytoskeleton Activation and Tumor Progression. In Hyaluronan in Cancer Biology, 1st; Stern, R., Ed.; Academic Press/Elsevier: San Diego, CA, USA, 2009; pp. 89–107.
[77]
Toole, B.P.; Slomiany, M.G. Hyaluronan, CD44 and Emmprin: Partners in cancer cell chemoresistance. Drug Resist. Updat. 2008, 11, 110–121, doi:10.1016/j.drup.2008.04.002.
[78]
Bourguignon, L.Y.; Lokeshwar, V.B.; He, J.; Chen, X.; Bourguignon, G.J. A CD44-like endothelial cell transmembrane glycoprotein (GP116) interacts with extracellular matrix and ankyrin. Mol. Cell. Biol. 1992, 12, 4464–4471.
[79]
Tsukita, S.; Oishi, K.; Sato, N.; Sagara, J.; Kawai, A.; Tsukita, S. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J. Cell Biol. 1994, 126, 391–401, doi:10.1083/jcb.126.2.391.
[80]
Maxwell, C.A.; McCarthy, J.; Turley, E. Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? J. Cell Sci. 2008, 121, 925–932, doi:10.1242/jcs.022038.
[81]
Hall, C.L.; Wang, C.; Lange, L.A.; Turley, E.A. Hyaluronan and the hyaluronan receptor RHAMM promote focal adhesion turnover and transient tyrosine kinase activity. J. Cell Biol. 1994, 126, 575–588.
[82]
Hall, C.L.; Wang, F.S.; Turley, E. Src？/？ fibroblasts are defective in their ability to disassemble focal adhesions in response to phorbol ester/hyaluronan treatment. Cell Commun. Adhes. 2002, 9, 273–283.
[83]
Itano, N.; Sawai, T.; Atsumi, F.; Miyaishi, O.; Taniguchi, S.; Kannagi, R.; Hamaguchi, M.; Kimata, K. Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J. Biol. Chem. 2004, 279, 18679–18687.
[84]
Maxwell, C.A.; Keats, J.J.; Crainie, M.; Sun, X.; Yen, T.; Shibuya, E.; Hendzel, M.; Chan, G.; Pilarski, L.M. RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Mol. Biol. Cell 2003, 14, 2262–2276.
[85]
Tolg, C.; Hamilton, S.R.; Morningstar, L.; Zhang, J.; Zhang, S.; Esguerra, K.V.; Telmer, P.G.; Luyt, L.G.; Harrison, R.; McCarthy, J.B.; et al. RHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activity. J. Biol. Chem. 2010, 285, 26461–26474.
Maxwell, C.A.; Benítez, J.; Gómez-Baldó, L.; Osorio, A.; Bonifaci, N.; Fernández-Ramires, R.; Costes, S.V.; Guinó, E.; Chen, H.; Evans, G.J.; et al. Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol. 2011, 9, e1001199.
[88]
Pujana, M.A.; Han, J.D.; Starita, L.M.; Stevens, K.N.; Tewari, M.; Ahn, J.S.; Rennert, G.; Moreno, V.; Kirchhoff, T.; Gold, B.; et al. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat. Genet. 2007, 39, 1338–1349.
[89]
Hamilton, S.R.; Fard, S.F.; Paiwand, F.F.; Tolg, C.; Veiseh, M.; Wang, C.; McCarthy, J.B.; Bissell, M.J.; Koropatnick, J.; Turley, E.A. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J. Biol. Chem. 2007, 282, 16667–16680.
[90]
Jiang, D.; Liang, J.; Fan, J.; Yu, S.; Chen, S.; Luo, Y.; Prestwich, G.D.; Mascarenhas, M.M.; Garg, H.G.; Quinn, D.A.; et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat. Med. 2005, 11, 1173–1179.
[91]
Jiang, D.; Liang, J.; Noble, P.W. Hyaluronan as an immune regulator in human diseases. Physiol. Rev. 2011, 91, 221–264, doi:10.1152/physrev.00052.2009.
[92]
Termeer, C.; Benedix, F.; Sleeman, J.; Fieber, C.; Voith, U.; Ahrens, T.; Miyake, K.; Freudenberg, M.; Galanos, C.; Simon, J.C. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J. Exp. Med. 2002, 195, 99–111, doi:10.1084/jem.20001858.
[93]
Kouvidi, K.; Berdiaki, A.; Nikitovic, D.; Katonis, P.; Afratis, N.; Hascall, V.C.; Karamanos, N.K.; Tzanakakis, G.N. Role of receptor for hyaluronic acid-mediated motility (RHAMM) in low molecular weight hyaluronan (LMWHA)-mediated fibrosarcoma cell adhesion. J. Biol. Chem. 2011, 286, 38509–38520.
[94]
Gao, F.; Yang, C.X.; Mo, W.; Liu, Y.W.; He, Y.Q. Hyaluronan oligosaccharides are potential stimulators to angiogenesis via RHAMM mediated signal pathway in wound healing. Clin. Invest. Med. 2008, 31, E106–E116.
[95]
Lokeshwar, V.B.; Selzer, M.G. Differences in hyaluronic acid-mediated functions and signaling in arterial, microvessel, and vein-derived human endothelial cells. J. Biol. Chem. 2000, 275, 27641–27649.
[96]
Wang, W.; Xu, G.L.; Jia, W.D.; Ma, J.L.; Li, J.S.; Ge, Y.S.; Ren, W.H.; Yu, J.H.; Liu, W.B. Ligation of TLR2 by versican: A link between inflammation and metastasis. Arch. Med. Res. 2009, 40, 321–323, doi:10.1016/j.arcmed.2009.04.005.
[97]
Critchley, D.R. Cytoskeletal proteins talin and vinculin in integrin-mediated adhesion. Biochem. Soc. Trans. 2004, 32, 831–836, doi:10.1042/BST0320831.
[98]
Hirose, Y.; Saijou, E.; Sugano, Y.; Takeshita, F.; Nishimura, S.; Nonaka, H.; Chen, Y.R.; Sekine, K.; Kido, T.; Nakamura, T.; et al. Inhibition of Stabilin-2 elevates circulating hyaluronic acid levels and prevents tumor metastasis. Proc. Natl. Acad. Sci. USA 2012, 109, 4263–4268.
[99]
Chen, Y.B.; Jiang, C.T.; Zhang, G.Q.; Wang, J.S.; Pang, D. Increased expression of hyaluronic acid binding protein 1 is correlated with poor prognosis in patients with breast cancer. J. Surg. Oncol. 2009, 100, 382–386, doi:10.1002/jso.21329.
[100]
Kim, K.B.; Yi, J.S.; Nguyen, N.; Lee, J.H.; Kwon, Y.C.; Ahn, B.Y.; Cho, H.; Kim, Y.K.; Yoo, H.J.; Lee, J.S.; et al. Cell-surface receptor for complement component C1q (gC1qR) is a key regulator for lamellipodia formation and cancer metastasis. J. Biol. Chem. 2011, 286, 23093–23101.
[101]
Truedsson, E. A case of mesothelioma of the pleura and peritoneum producing hyaluronic acid. Acta Soc. Med. Ups. 1951, 56, 39–45.
[102]
Jensen, C.E. Hyaluronic acid. IV. Isolation of hyaluronic acid from pseudomucinous ovarian cysts. Acta Pharmacol. Toxicol. (Copenh.) 1954, 10, 83–88.
[103]
Pillwein, K.; Fuiko, R.; Slavc, I.; Czech, T.; Hawliczek, G.; Bernhardt, G.; Nirnberger, G.; K？ller, U. Hyaluronidase additional to standard chemotherapy improves outcome for children with malignant brain tumors. Cancer Lett. 1998, 131, 101–108, doi:10.1016/S0304-3835(98)00205-5.
[104]
Baumgartner, G.; Gomar-H？ss, C.; Sakr, L.; Ulsperger, E.; Wogritsch, C. The impact of extracellular matrix on the chemoresistance of solid tumors—Experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett. 1998, 131, 85–99, doi:10.1016/S0304-3835(98)00204-3.
[105]
Klocker, J.; Sabitzer, H.; Raunik, W.; Wieser, S.; Schumer, J. Hyaluronidase as additive to induction chemotherapy in advanced squamous cell carcinoma of the head and neck. Cancer Lett. 1998, 131, 113–115, doi:10.1016/S0304-3835(98)00207-9.
[106]
Spruss, T.; Bernhardt, G.; Sch？nenberger, H.; Schiess, W. Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma. J. Cancer Res. Clin. Oncol. 1995, 121, 193–202, doi:10.1007/BF01366962.
[107]
Brekken, C.; de Lange Davies, C. Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner. Cancer Lett. 1998, 131, 65–70, doi:10.1016/S0304-3835(98)00202-X.
[108]
Eikenes, L.; Tari, M.; Tufto, I.; Bruland, O.S.; de Lange Davies, C. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br. J. Cancer 2005, 93, 81–88, doi:10.1038/sj.bjc.6602626.
[109]
Kosaki, R.; Watanabe, K.; Yamaguchi, Y. Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Cancer Res. 1999, 59, 1141–1145.
[110]
Koyama, H.; Kobayashi, N.; Harada, M.; Takeoka, M.; Kawai, Y.; Sano, K.; Fujimori, M.; Amano, J.; Ohhashi, T.; Kannagi, R.; et al. Significance of tumor-associated stroma in promotion of intratumoral lymphangiogenesis: Pivotal role of a hyaluronan-rich tumor microenvironment. Am. J. Pathol. 2008, 172, 179–193, doi:10.2353/ajpath.2008.070360.
[111]
Shuster, S.; Frost, G.I.; Csoka, A.B.; Formby, B.; Stern, R. Hyaluronidase reduces human breast cancer xenografts in SCID mice. Int. J. Cancer 2002, 102, 192–197, doi:10.1002/ijc.10668.
[112]
Simpson, M.A.; Wilson, C.M.; McCarthy, J.B. Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am. J. Pathol. 2002, 161, 849–857.
[113]
Kim, H.R.; Wheeler, M.A.; Wilson, C.M.; Iida, J.; Eng, D.; Simpson, M.A.; McCarthy, J.B.; Bullard, K.M. Hyaluronan facilitates invasion of colon carcinoma cells in vitro via interaction with CD44. Cancer Res. 2004, 64, 4569–4576.
[114]
Nishida, Y.; Knudson, W.; Knudson, C.B.; Ishiguro, N. Antisense inhibition of hyaluronan synthase-2 in human osteosarcoma cells inhibits hyaluronan retention and tumorigenicity. Exp. Cell Res. 2005, 307, 194–203, doi:10.1016/j.yexcr.2005.03.026.
[115]
Udabage, L.; Brownlee, G.R.; Nilsson, S.K.; Brown, T.J. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp. Cell Res. 2005, 310, 205–217, doi:10.1016/j.yexcr.2005.07.026.
[116]
Kudo, D.; Kon, A.; Yoshihara, S.; Kakizaki, I.; Sasaki, M.; Endo, M.; Takagaki, K. Effect of a hyaluronan synthase suppressor, 4-methylumbelliferone, on B16F-10 melanoma cell adhesion and locomotion. Biochem. Biophys. Res. Commun. 2004, 321, 783–787.
[117]
Urakawa, H.; Nishida, Y.; Wasa, J.; Arai, E.; Zhuo, L.; Kimata, K.; Kozawa, E.; Futamura, N.; Ishiguro, N. Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Int. J. Cancer 2012, 130, 454–466, doi:10.1002/ijc.26014.
[118]
Kultti, A.; Pasonen-Sepp？nen, S.; Jauhiainen, M.; Rilla, K.J.; K？rn？, R.; Py？ri？, E.; Tammi, R.H.; Tammi, M.I. 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp. Cell Res. 2009, 315, 1914–1923, doi:10.1016/j.yexcr.2009.03.002.
[119]
Yoshihara, S.; Kon, A.; Kudo, D.; Nakazawa, H.; Kakizaki, I.; Sasaki, M.; Endo, M.; Takagaki, K. A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells. FEBS Lett. 2005, 579, 2722–2726.
[120]
Auvinen, P.; Tammi, R.; Parkkinen, J.; Tammi, M.; Agren, U.; Johansson, R.; Hirvikoski, P.; Eskelinen, M.; Kosma, V.M. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am. J. Pathol. 2000, 156, 529–536, doi:10.1016/S0002-9440(10)64757-8.
[121]
Set？l？, L.P.; Tammi, M.I.; Tammi, R.H.; Eskelinen, M.J.; Lipponen, P.K.; Agren, U.M.; Parkkinen, J.; Alhava, E.M.; Kosma, V.M. Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate. Br. J. Cancer 1999, 79, 1133–1138.
[122]
Ropponen, K.; Tammi, M.; Parkkinen, J.; Eskelinen, M.; Tammi, R.; Lipponen, P.; Agren, U.; Alhava, E.; Kosma, V.M. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res. 1998, 58, 342–347.
[123]
Anttila, M.A.; Tammi, R.H.; Tammi, M.I.; Syrj？nen, K.J.; Saarikoski, S.V.; Kosma, V.M. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res. 2000, 60, 150–155.
[124]
Josefsson, A.; Adamo, H.; Hammarsten, P.; Granfors, T.; Stattin, P.; Egevad, L.; Laurent, A.E.; Wikstr？m, P.; Bergh, A. Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome. Am. J. Pathol. 2011, 179, 1961–1968.
[125]
Kramer, M.W.; Escudero, D.O.; Lokeshwar, S.D.; Golshani, R.; Ekwenna, O.O.; Acosta, K.; Merseburger, A.S.; Soloway, M.; Lokeshwar, V.B. Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer 2011, 117, 1197–1209.
[126]
Pirinen, R.; Tammi, R.; Tammi, M.; Hirvikoski, P.; Parkkinen, J.J.; Johansson, R.; B？hm, J.; Hollmén, S.; Kosma, V.M. Prognostic value of hyaluronan expression in non-small-cell lung cancer: Increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int. J. Cancer 2001, 95, 12–17, doi:10.1002/1097-0215(20010120)95:1<12::AID-IJC1002>3.0.CO;2-E.
[127]
Hertweck, M.K.; Erdfelder, F.; Kreuzer, K.A. CD44 in hematological neoplasias. Ann. Hematol. 2011, 90, 493–508, doi:10.1007/s00277-011-1161-z.
[128]
Tzankov, A.; Strasser, U.; Dirnhofer, S.; Menter, T.; Arber, C.; Jotterand, M.; Rovo, A.; Tichelli, A.; Stauder, R.; Günthert, U. In situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survival. Ann. Hematol. 2011, 90, 901–909, doi:10.1007/s00277-011-1159-6.
[129]
Lugli, A.; Zlobec, I.; Günthert, U.; Minoo, P.; Baker, K.; Tornillo, L.; Terracciano, L.; Jass, J.R. Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancer. Mod. Pathol. 2006, 19, 1302–1309, doi:10.1038/modpathol.3800648.
[130]
Godar, S.; Ince, T.A.; Bell, G.W.; Feldser, D.; Donaher, J.L.; Bergh, J.; Liu, A.; Miu, K.; Watnick, R.S.; Reinhardt, F.; et al. Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008, 134, 62–73, doi:10.1016/j.cell.2008.06.006.
[131]
Sohr, S.; Engeland, K. RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53. Cell Cycle 2008, 7, 3448–3460, doi:10.4161/cc.7.21.7014.
[132]
Willenberg, A.; Saalbach, A.; Simon, J.C.; Anderegg, U. Melanoma cells control HA synthesis in peritumoral fibroblasts via PDGF-AA and PDGF-CC: Impact on melanoma cell proliferation. J. Invest. Dermatol. 2012, 132, 385–393, doi:10.1038/jid.2011.325.
[133]
Hingorani, S.R.; Wang, L.; Multani, A.S.; Combs, C.; Deramaudt, T.B.; Hruban, R.H.; Rustgi, A.K.; Chang, S.; Tuveson, D.A. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7, 469–483, doi:10.1016/j.ccr.2005.04.023.
[134]
Olive, K.P.; Jacobetz, M.A.; Davidson, C.J.; Gopinathan, A.; McIntyre, D.; Honess, D.; Madhu, B.; Goldgraben, M.A.; Caldwell, M.E.; Allard, D.; et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324, 1457–1461.
[135]
Beckenlehner, K.; Bannke, S.; Spruss, T.; Bernhardt, G.; Sch？nenberg, H.; Schiess, W. Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo. J. Cancer Res. Clin. Oncol. 1992, 118, 591–596.
[136]
Smith, K.J.; Skelton, H.G.; Turiansky, G.; Wagner, K.F. Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi’s sarcoma. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). J. Am. Acad. Dermatol. 1997, 36, 239–242.
[137]
Novak, U.; Stylli, S.S.; Kaye, A.H.; Lepperdinger, G. Hyaluronidase-2 overexpression accelerates intracerebral but not subcutaneous tumor formation of murine astrocytoma cells. Cancer Res. 1999, 59, 6246–6250.
[138]
Tan, J.X.; Wang, X.Y.; Li, H.Y.; Su, X.L.; Wang, L.; Ran, L.; Zheng, K.; Ren, G.S. HYAL1 overexpression is correlated with the malignant behavior of human breast cancer. Int. J. Cancer 2011, 128, 1303–1315, doi:10.1002/ijc.25460.
[139]
Lokeshwar, V.B.; Young, M.J.; Goudarzi, G.; Iida, N.; Yudin, A.I.; Cherr, G.N.; Selzer, M.G. Identification of bladder tumor-derived hyaluronidase: Its similarity to HYAL1. Cancer Res. 1999, 59, 4464–4470.
[140]
Lokeshwar, V.B.; Rubinowicz, D.; Schroeder, G.L.; Forgacs, E.; Minna, J.D.; Block, N.L.; Nadji, M.; Lokeshwar, B.L. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J. Biol. Chem. 2001, 276, 11922–11932.
[141]
Benitez, A.; Yates, T.J.; Lopez, L.E.; Cerwinka, W.H.; Bakkar, A.; Lokeshwar, V.B. Targeting hyaluronidase for cancer therapy: Antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res. 2011, 71, 4085–4095.
[142]
Lokeshwar, V.B.; Lokeshwar, B.L.; Pham, H.T.; Block, N.L. Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression. Cancer Res. 1996, 56, 651–657.
[143]
Droller, M.J. Tumor-derived hyaluronidase: A diagnostic urine marker for high-grade bladder cancer. J. Urol. 1998, 160, 619–620.
[144]
Franzmann, E.J.; Schroeder, G.L.; Goodwin, W.J.; Weed, D.T.; Fisher, P.; Lokeshwar, V.B. Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int. J. Cancer 2003, 106, 438–445, doi:10.1002/ijc.11252.
[145]
Bertrand, P.; Girard, N.; Duval, C.; d’Anjou, J.; Chauzy, C.; Ménard, J.F.; Delpech, B. Increased hyaluronidase levels in breast tumor metastases. Int. J. Cancer 1997, 73, 327–331, doi:10.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO;2-1.
[146]
Delpech, B.; Laquerriere, A.; Maingonnat, C.; Bertrand, P.; Freger, P. Hyaluronidase is more elevated in human brain metastases than in primary brain tumours. Anticancer Res. 2002, 22, 2423–2427.
[147]
Pham, H.T.; Block, N.L.; Lokeshwar, V.B. Tumor-derived hyaluronidase: A diagnostic urine marker for high-grade bladder cancer. Cancer Res. 1997, 57, 778–783.
[148]
Stern, M.; Longaker, M.T.; Adzick, N.S.; Harrison, M.R.; Stern, R. Hyaluronidase levels in urine from Wilms’ tumor patients. J. Natl. Cancer Inst. 1991, 83, 1569–1574, doi:10.1093/jnci/83.21.1569.
[149]
Nykopp, T.K.; Rilla, K.; Sironen, R.; Tammi, M.I.; Tammi, R.H.; H？m？l？inen, K.; Heikkinen, A.M.; Komulainen, M.; Kosma, V.M.; Anttila, M. Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: Inverse correlation between HYAL1 and hyaluronan content. BMC Cancer 2009, 9, 143.
[150]
Lokeshwar, V.B.; Selzer, M.G. Hyaluronidase: Both a tumor promoter and suppressor. Semin. Cancer Biol. 2008, 18, 281–287, doi:10.1016/j.semcancer.2008.03.008.
[151]
Jacobson, A.; Rahmanian, M.; Rubin, K.; Heldin, P. Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. Int. J. Cancer 2002, 102, 212–219, doi:10.1002/ijc.10683.
[152]
Lokeshwar, V.B.; Cerwinka, W.H.; Isoyama, T.; Lokeshwar, B.L. HYAL1 hyaluronidase in prostate cancer: A tumor promoter and suppressor. Cancer Res. 2005, 65, 7782–7789.
[153]
Camenisch, T.D.; McDonald, J.A. Hyaluronan: Is bigger better? Am. J. Respir. Cell Mol. Biol. 2000, 23, 431–433.
[154]
Deed, R.; Rooney, P.; Kumar, P.; Norton, J.D.; Smith, J.; Freemont, A.J.; Kumar, S. Early-response gene signalling is induced by angiogenic oligosaccharides of hyaluronan in endothelial cells. Inhibition by non-angiogenic, high-molecular-weight hyaluronan. Int. J. Cancer 1997, 71, 251–256.
[155]
Rooney, P.; Kumar, S.; Ponting, J.; Wang, M. The role of hyaluronan in tumour neovascularization (review). Int. J. Cancer 1995, 60, 632–636, doi:10.1002/ijc.2910600511.
[156]
Matou-Nasri, S.; Gaffney, J.; Kumar, S.; Slevin, M. Oligosaccharides of hyaluronan induce angiogenesis through distinct CD44 and RHAMM-mediated signalling pathways involving Cdc2 and gamma-adducin. Int. J. Oncol. 2009, 35, 761–773.
[157]
Rahmanian, M.; Pertoft, H.; Kanda, S.; Christofferson, R.; Claesson-Welsh, L.; Heldin, P. Hyaluronan oligosaccharides induce tube formation of a brain endothelial cell line in vitro. Exp. Cell Res. 1997, 237, 223–230, doi:10.1006/excr.1997.3792.
[158]
Rooney, P.; Wang, M.; Kumar, P.; Kumar, S. Angiogenic oligosaccharides of hyaluronan enhance the production of collagens by endothelial cells. J. Cell Sci. 1993, 105, 213–218.
[159]
Lokeshwar, V.B.; Obek, C.; Soloway, M.S.; Block, N.L. Tumor-associated hyaluronic acid: A new sensitive and specific urine marker for bladder cancer. Cancer Res. 1997, 57, 773–777.
[160]
Urakawa, H.; Nishida, Y.; Knudson, W.; Knudson, C.B.; Arai, E.; Kozawa, E.; Futamura, N.; Wasa, J.; Ishiguro, N. Therapeutic potential of hyaluronan oligosaccharides for bone metastasis of breast cancer. J. Orthop. Res. 2012, 30, 662–672.
[161]
Zeng, C.; Toole, B.P.; Kinney, S.D.; Kuo, J.W.; Stamenkovic, I. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int. J. Cancer 1998, 77, 396–401.
[162]
Slomiany, M.G.; Dai, L.; Tolliver, L.B.; Grass, G.D.; Zeng, Y.; Toole, B.P. Inhibition of functional hyaluronan-CD44 interactions in CD133-positive primary human ovarian carcinoma cells by small hyaluronan oligosaccharides. Clin. Cancer Res. 2009, 15, 7593–7601, doi:10.1158/1078-0432.CCR-09-2317.
[163]
Hosono, K.; Nishida, Y.; Knudson, W.; Knudson, C.B.; Naruse, T.; Suzuki, Y.; Ishiguro, N. Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells. Am. J. Pathol. 2007, 171, 274–286, doi:10.2353/ajpath.2007.060828.
[164]
Slomiany, M.G.; Dai, L.; Bomar, P.A.; Knackstedt, T.J.; Kranc, D.A.; Tolliver, L.; Maria, B.L.; Toole, B.P. Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. Cancer Res. 2009, 69, 4992–4998, doi:10.1158/0008-5472.CAN-09-0143.
[165]
Ghatak, S.; Misra, S.; Toole, B.P. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J. Biol. Chem. 2002, 277, 38013–38020.
[166]
Misra, S.; Ghatak, S.; Zoltan-Jones, A.; Toole, B.P. Regulation of multidrug resistance in cancer cells by hyaluronan. J. Biol. Chem. 2003, 278, 25285–25288.
[167]
Stern, R.; Asari, A.A.; Sugahara, K.N. Hyaluronan fragments: An information-rich system. Eur. J. Cell Biol. 2006, 85, 699–715, doi:10.1016/j.ejcb.2006.05.009.
[168]
Rembrink, K.; Romijn, J.C.; van der Kwast, T.H.; Rübben, H.; Schr？der, F.H. Orthotopic implantation of human prostate cancer cell lines: A clinically relevant animal model for metastatic prostate cancer. Prostate 1997, 31, 168–174, doi:10.1002/(SICI)1097-0045(19970515)31:3<168::AID-PROS4>3.0.CO;2-H.
[169]
Cos, S.; Fernández, R.; Güézmes, A.; Sánchez-Barceló, E.J. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res. 1998, 58, 4383–4390.
[170]
Richter, U.; Wicklein, D.; Geleff, S.; Schumacher, U. The interaction between CD44 on tumour cells and hyaluronan under physiologic flow conditions: Implications for metastasis formation. Histochem. Cell Biol. 2012, 137, 687–695, doi:10.1007/s00418-012-0916-5.
[171]
Stephenson, R.A.; Dinney, C.P.; Gohji, K.; Ordó？ez, N.G.; Killion, J.J.; Fidler, I.J. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J. Natl. Cancer Inst. 1992, 17, 951–957.
[172]
Veiseh, M.; Turley, E.A. Hyaluronan metabolism in remodeling extracellular matrix: Probes for imaging and therapy of breast cancer. Integr. Biol. (Camb.) 2011, 4, 304–315.
